GOSS Gossamer Bio, Inc.
USHealthcareAs of 2026-07-10 15:00
Why GOSS matters now
Gossamer Bio, Inc. (GOSS) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.17 with -4.46% on the session and $39.2M in market capitalization; recent performance reads 1-month -15.62% and YTD -94.58%.
The latest financial table shown here is Q1 2026, with revenue of $17.0M, net income of $-46.7M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -432.2%.
The latest indexable market news headline is "Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $1.00; recent insider activity includes Nathan Steven D filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.24
P/S
0.71
EV/EBITDA
-1.19
DCF Value
$1.35
FCF Yield
-432.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.6%
Operating Margin
-321.9%
Net Margin
-324.8%
ROE
174.9%
ROA
-140.0%
ROIC
-243.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.0M | $-46.7M | $-0.20 |
| Q4 2025 | $13.8M | $-47.2M | $-0.21 |
| FY 2025 | $48.5M | $-170.4M | $-0.75 |
| Q3 2025 | $13.3M | $-48.2M | $-0.21 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$0.77
Target (Median)
$1.00
Target Range
$0.30 - $1.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.00
Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company. Its primary objective is to discover, acquire, advance, and market novel therapeutic solutions, specifically addressing conditions within immunology, inflammatory diseases, and oncology. The company's pipeline highlights several key drug candidates: GB002: An inhaled small molecule designed to inhibit platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, currently being developed for pulmonary arterial hypertension. GB004: An oral, gut-targeted small molecule in development for treating inflammatory bowel disease. GB5121: An oral, irreversible covalent small molecule that targets Bruton's Tyrosine Kinase (BTK), intended for primary central nervous system lymphoma. GB7208: Another oral small molecule BTK inhibitor, under investigation for multiple sclerosis. To support its drug development initiatives, Gossamer Bio has forged strategic licensing partnerships. It holds agreements with Pulmokine, Inc. for the advancement and commercialization of GB002 and its associated backup compounds. Additionally, the company collaborates with Aerpio Pharmaceuticals, Inc. regarding GB004 and related chemical entities. Founded in 2015, the enterprise was initially known as FSG, Bio, Inc. before rebranding as Gossamer Bio, Inc. in 2017. Its corporate headquarters are situated in San Diego, California.